June 9, 2026
Gad Berdugo, MSc Eng., MBA, joins as an independent board member in connection with an investment from Explorium Capital LLC through the Cane Angel Network. He brings over 30 years of leadership in biotechnology, RNA therapeutics, and capital markets — including senior roles at Editas Medicine, Abbott Laboratories, and Baxter International.
July 21, 2026
Founder and CEO Sid Kerkar, M.D., will present AllerGene’s in vivo mRNA-LNP CAR-T platform at Hanson Wade’s 5th In Vivo Cell Engineering & Gene Editing Summit, July 28–30, 2026, in Boston. His talk, scheduled for July 30 at 11:00 a.m., will cover the company’s approach to engineering CAR-T cells directly in the body to selectively target disease-driving mast cells — a potential new treatment path for mastocytosis, chronic urticaria, food allergies, allergic asthma, and anaphylaxis.
July 21, 2026
Founder and CEO Sid Kerkar, M.D., will present AllerGene’s in vivo mRNA-LNP CAR-T platform at Hanson Wade’s 5th In Vivo Cell Engineering & Gene Editing Summit, July 28–30, 2026, in Boston. His talk, scheduled for July 30 at 11:00 a.m., will cover the company’s approach to engineering CAR-T cells directly in the body to selectively target disease-driving mast cells — a potential new treatment path for mastocytosis, chronic urticaria, food allergies, allergic asthma, and anaphylaxis.